SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

Search

Pharma Mar SA

Atidarymo kaina

78.75 -3.26

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

77.6

Max

82.25

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.7M

9.5M

Pardavimai

2.7M

48M

P/E

Sektoriaus vid.

1,996.25

73.239

Pelnas, tenkantis vienai akcijai

1.063

Dividendų pajamingumas

0.81

Pelno marža

19.737

Darbuotojai

500

EBITDA

8.2M

15M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+29.81% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.81%

3.06%

Kitas uždarbis

2025-04-22

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.4B

Ankstesnė atidarymo kaina

82.01

Ankstesnė uždarymo kaina

78.75

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Pharma Mar SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-01 23:15; UTC

Pagrindinės rinkos jėgos

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025-04-01 23:46; UTC

Rinkos pokalbiai

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025-04-01 23:43; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

2025-04-01 23:11; UTC

Svarbiausios naujienos

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

2025-04-01 23:02; UTC

Rinkos pokalbiai

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

2025-04-01 22:31; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 22:26; UTC

Rinkos pokalbiai

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

2025-04-01 21:47; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 21:32; UTC

Svarbiausios naujienos

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

2025-04-01 21:06; UTC

Rinkos pokalbiai

Mexican Remittances See Slow Start to the Year -- Market Talk

2025-04-01 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-04-01 20:47; UTC

Svarbiausios naujienos

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

2025-04-01 20:47; UTC

Svarbiausios naujienos

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

2025-04-01 20:20; UTC

Svarbiausios naujienos

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

2025-04-01 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Fibrebond >ETN

2025-04-01 20:11; UTC

Rinkos pokalbiai

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

2025-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

2025-04-01 20:00; UTC

Svarbiausios naujienos

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

2025-04-01 19:46; UTC

Svarbiausios naujienos

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

2025-04-01 19:43; UTC

Rinkos pokalbiai

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

2025-04-01 19:17; UTC

Svarbiausios naujienos

Meta's Head of AI Research to Resign Amid Computing Push -- Update

2025-04-01 19:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Give Back Gains -- Market Talk

2025-04-01 19:03; UTC

Rinkos pokalbiai

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

2025-04-01 19:00; UTC

Rinkos pokalbiai

Gold Slips Ahead of Tariff Day -- Market Talk

2025-04-01 18:54; UTC

Rinkos pokalbiai

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Akcijų palyginimas

Kainos pokytis

Pharma Mar SA Prognozė

Kainos tikslas

By TipRanks

29.81% į viršų

12 mėnesių prognozė

Vidutinis 108.004 EUR  29.81%

Aukščiausias 108 EUR

Žemiausias 108 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pharma Mar SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

80.7 / 90.2Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.